# Yonsei whole-genome cell-free DNA multi-cancer platform: development, validation and confirmation

Source: https://onco.cc/trials/yonsei-mced-wgs-2/  
OnCo record `yonsei-mced-wgs-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A larger South Korean follow-on study developing and validating an artificial intelligence blood test for many cancers.

## Summary

Yonsei whole-genome cell-free DNA multi-cancer platform: development, validation and confirmation (NCT07598747) is an observational study sponsored by Chang Gon Kim. It builds a database of circulating DNA from people with and without cancer and develops and validates an artificial intelligence platform to detect cancers early.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 6,000 participants, a start on 14 October 2024 and primary completion expected on 13 October 2029.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Registry id: NCT07598747
- Phase: observational
- Setting: People with cancer and people without cancer in South Korea, building a clinical and molecular database and an artificial intelligence classifier
- Sponsor: Chang Gon Kim
- Enrolled: 6000

## Sources

- ClinicalTrials.gov NCT07598747: https://clinicaltrials.gov/study/NCT07598747

## Connected records

- trials: [Yonsei whole-genome cell-free DNA multi-cancer platform study](https://onco.cc/trials/yonsei-mced-wgs/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/yonsei-mced-wgs-2.json